SeaStar Medical (ICU) Expected to Announce Earnings on Thursday

SeaStar Medical (NASDAQ:ICU) is anticipated to announce its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect SeaStar Medical to post earnings of ($0.95) per share and revenue of $0.50 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 11, 2026 at 4:30 PM ET.

SeaStar Medical (NASDAQ:ICU) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.06. The business had revenue of $0.61 million during the quarter, compared to analyst estimates of $0.49 million. SeaStar Medical had a negative return on equity of 162.75% and a negative net margin of 795.51%. On average, analysts expect SeaStar Medical to post ($3.66) EPS for the current fiscal year and ($2.09) EPS for the next fiscal year.

SeaStar Medical Trading Up 2.0%

Shares of ICU opened at $2.04 on Thursday. The business’s 50-day moving average price is $3.13 and its 200 day moving average price is $3.30. The stock has a market capitalization of $10.85 million, a P/E ratio of -0.52 and a beta of -1.07. SeaStar Medical has a 1-year low of $1.90 and a 1-year high of $5.40.

Analysts Set New Price Targets

ICU has been the subject of several recent analyst reports. Wall Street Zen upgraded shares of SeaStar Medical from a “sell” rating to a “hold” rating in a report on Saturday, September 19th. Weiss Ratings restated a “sell (e+)” rating on shares of SeaStar Medical in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, SeaStar Medical currently has an average rating of “Hold” and a consensus price target of $8.00.

About SeaStar Medical

SeaStar Medical Holding Corporation (NASDAQ: ICU) is a medical technology company developing therapies designed to address hyperinflammation, an excessive immune response that can contribute to organ damage in critically ill patients. The company’s platform is intended to selectively target and modulate pro-inflammatory immune cells while preserving the body’s broader immune function.

Its lead product is the Selective Cytopheretic Device (SCD), an extracorporeal blood-purification device used alongside continuous kidney replacement therapy.